HTML Microdata document

This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n8	http://linked.opendata.cz/resource/drugbank/drug/DB05462/identifier/drugbank/
n10	http://bio2rdf.org/drugbank:
adms	http://www.w3.org/ns/adms#
n7	http://linked.opendata.cz/resource/drugbank/drug/DB05462/identifier/chemspider/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
owl	http://www.w3.org/2002/07/owl#
n5	http://linked.opendata.cz/ontology/drugbank/
n6	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n4	http://linked.opendata.cz/resource/drugbank/drug/DB05462/identifier/pubchem-compound/

Statements

Subject Item: n2:DB05462
rdf:type: n5:Drug
n5:description: 131-I-TM-601 is investigated in clinical trials for treating brain cancer. 131-I-TM-601 is a solid. Tx binds to and reduces the activity of a matrix metalloproteinase (MMP) that regulates functioning of the chloride channels on cell membranes. TM-601 is a small 36-amino-acid peptide that selectively binds to glioma cells but not normal brain parenchyma. It is a synthetic version of a neurotoxin isolated from the venom of the Giant Yellow Israeli scorpion Leiurus quinquestriatus. The synthetic version of this peptide has been manufactured and covalently linked to iodine 131 ((131)I-TM-601) as a means of targeting radiation to tumor cells in the treatment of brain cancer. The selective effects of TM-601 are regulated by its action on MMP2 receptors.
n5:generalReferences: # Mamelak AN, Jacoby DB: Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007 Mar;4(2):175-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17335414 # Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA: Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. 2006 Aug 1;24(22):3644-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16877732 # Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 1998 Nov 1;58(21):4871-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9809993 # TransMolecular receives FDA approval for 131-I-TM-601 IND application. Expert Rev Anticancer Ther. 2002 Apr;2(2):139. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12113233
n5:group: investigational
n5:indication: Investigated for use/treatment in various forms of brain cancer; Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
owl:sameAs: n10:DB05462
dcterms:title: 131-I-TM-601
adms:identifier: n4:4369566 n7:3572093 n8:DB05462
n5:mechanismOfAction: TX binds to and reduces the activity of a matrix metalloproteinase (MMP) that is regulates functioning of the chloride channels on cell membranes. CTX reduced the migration ability of glioma cells through tight extracellular spaces in the brain tissue by inhibition of the MMP2, because this prevented the cells from shrinking and releasing from the extracellular matrix.
n5:synonym: TM-601
n5:toxicity: Found safe in clinical trials.
n5:IUPAC-Name: n6:271B4478-363D-11E5-9242-09173F13E4C5
n5:InChI: n6:271B447E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula: n6:271B447D-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight: n6:271B447A-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight: n6:271B447B-363D-11E5-9242-09173F13E4C5
n5:SMILES: n6:271B447C-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility: n6:271B4476-363D-11E5-9242-09173F13E4C5
n5:logP: n6:271B4477-363D-11E5-9242-09173F13E4C5 n6:271B4474-363D-11E5-9242-09173F13E4C5
n5:logS: n6:271B4475-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count: n6:271B4484-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count: n6:271B4485-363D-11E5-9242-09173F13E4C5
n5:InChIKey: n6:271B447F-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-: n6:271B4480-363D-11E5-9242-09173F13E4C5
n5:Polarizability: n6:271B4482-363D-11E5-9242-09173F13E4C5
n5:Refractivity: n6:271B4481-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count: n6:271B4483-363D-11E5-9242-09173F13E4C5
n5:Bioavailability: n6:271B4489-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter: n6:271B448B-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule: n6:271B448C-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings: n6:271B4488-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge: n6:271B4487-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five: n6:271B448A-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name: n6:271B4479-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-: n6:271B4486-363D-11E5-9242-09173F13E4C5